By Elizabeth Bevins, M.D., Ph.D.
June 16, 2026
For years, my family played the game that millions of American households know all too well: we performed the dance of denial. When my father began making small, uncharacteristic mistakes, we leaned on the most convenient narrative available. We blamed his demanding work schedule, the relentless pressure of his career, and the general fatigue of middle age. It was a comforting lie, a way to keep the encroaching reality of neurodegeneration at bay.
But the veil of denial was shredded the week after my second daughter was born. My father came to meet his new grandchild. As he walked through the gate to our yard, he stopped to look at our small dog—an animal who had been a fixture in my home for years, a creature he should have known intimately. His expression wavered, flickering between recognition and confusion. Then, he looked at me and asked if I had recently acquired a new pet.
I am a faculty neurologist at the University of California, San Diego, specializing in Alzheimer’s disease. In that singular, devastating moment, I knew exactly what I was witnessing. Yet, the tragedy was not that I hadn’t noticed; the tragedy was that my profession had trained me—and the entire clinical system—to wait until the fire was already consuming the house before we even acknowledged the smoke.
The Chronology of a Silent Cascade
The common perception of Alzheimer’s disease is that of an ailment of the elderly, a thief that steals the memories of our twilight years. This is a profound clinical misunderstanding. The biology of Alzheimer’s is a long-game, a silent, decades-long biological process that reaches clinical visibility only when the brain has already sustained substantial, often irreversible injury.
My mother had raised concerns with his primary care physician multiple times. My father, maintaining a high "cognitive reserve," could still pass a standard cognitive screening test. His physician was not negligent; he was operating within a system that provided him with zero tools to act on a spouse’s intuition.
In hindsight, I realize the pathology began 15 to 20 years before the first overt symptoms appeared. My father’s disease was germinating in midlife, while he was still working, thriving, and raising his family. The clinical system taught me to look for unmistakable decline, a diagnostic threshold that essentially guarantees we miss the window of opportunity for meaningful intervention. We are currently calibrated to diagnose the aftermath of the disease, not its origin.
Supporting Data: A Paradigm Shift in Diagnostics
The scientific community has long understood the mechanics of this disease, even if our clinical pathways have lagged. Amyloid plaques accumulate, and tau protein pathology spreads through vulnerable neural networks years before a patient forgets a name or loses their way.
The Technological Leap
In 2025, the landscape shifted when the Food and Drug Administration (FDA) cleared the first blood-based biomarkers for Alzheimer’s disease. These tests, specifically designed for use in primary care settings, represent a watershed moment. While current indications remain focused on patients already showing symptoms, they act as a harbinger for a future where a routine blood draw could identify the pathological signature of Alzheimer’s years before the first memory lapse.
The Power of Risk Mitigation
We are not working in a vacuum. Large-scale population studies have identified clear, modifiable risk factors that account for a significant portion of dementia risk. These include:
- Cardiovascular and Metabolic Health: The health of the heart is inextricably linked to the health of the brain.
- Sleep Hygiene: Emerging research suggests sleep is the brain’s "waste management" system for amyloid proteins.
- Physical and Cognitive Engagement: Active neural networks show greater resilience against the spread of tau pathology.
Multidomain intervention trials have confirmed that targeting these factors can preserve cognitive function in at-risk populations. Furthermore, the AHEAD 3-45 clinical trial, which concluded recruitment in 2024, has been testing anti-amyloid therapies in presymptomatic individuals—a direct acknowledgement that we must shift our interventions to the earliest possible stage.
The Institutional Failure: Why We Lack a Path to Prevention
The primary issue is not a lack of scientific foundation, but a lack of systemic structure. Currently, no medical specialty "owns" the prevention of Alzheimer’s.
- The Primary Care Gap: General practitioners lack the specific tools and established guidelines to identify patients at elevated risk before symptoms manifest.
- The Specialist Disconnect: Neurologists typically see patients only after the "clinical visibility" threshold has been crossed.
- The Missing Pathway: I am frequently approached by the children of my patients—healthy, middle-aged adults who are watching their parents decline and are terrified for their own futures. Despite my expertise, I have no formal pathway to offer them for assessment or longitudinal monitoring.
The current system is reactive by design. We wait for the symptom, we diagnose the damage, and we attempt to manage the decline. This is the opposite of how we handle heart disease, where we monitor cholesterol and blood pressure decades before a potential cardiac event.
Implications: Building a New Model of Brain Health
To move forward, we must abandon the reactive model in favor of a longitudinal, preventative framework. This transition requires a fundamental shift in how we define "brain health" within the healthcare infrastructure.
The Three Pillars of Reform
- Structured Risk Assessment: Primary care must incorporate neuro-risk profiling into standard midlife check-ups.
- Specialized Referral Pathways: Just as we have cardiology clinics for heart health, we need dedicated pathways for those identified as high-risk, allowing for specialist evaluation that goes beyond basic cognitive testing.
- Evolutionary Care Plans: Treatment cannot be static. It must be a living, longitudinal plan that adjusts as individual biological trajectories evolve.
The Risks of Premature Action
However, we must proceed with intellectual honesty. A responsible prevention model must avoid two extremes: the continued reliance on reactive care, and the premature, over-eager adoption of interventions that lack sufficient evidence. Biomarkers should be used with clinical precision, and the inherent uncertainties of a pre-symptomatic diagnosis must be clearly communicated to patients. We must ensure that our interventions are proportionate to the strength of the scientific evidence.
Conclusion: The Biology Doesn’t Wait
My father is not an edge case. He is the face of this disease from the inside—a man whose brain resilience was slowly eroded by years of silent, accumulating pathology. The failure to intervene was not a failure of his physician’s character or my own clinical dedication; it was a failure of the system that governs our practice.
The biology of Alzheimer’s disease is relentless. It does not wait for us to update our guidelines, nor does it pause while we debate the ethics of pre-symptomatic testing. We are standing at a crossroads. We can continue to watch patients arrive at our doors only after their cognitive resilience has been depleted, or we can build a system that meets them in their midlife, where the opportunity for intervention is still vast.
At UC San Diego, I am currently working to build a prevention program called Brain Longevity. It is a small step, but it is one that recognizes a fundamental truth: if we want to change the story of Alzheimer’s, we must stop reading the final chapter and start writing the first. The time for reactive medicine has passed; the era of proactive brain health must begin.
